NeuroBo Pharmaceuticals Appoints New Director and CMO

TL;DR

NeuroBo beefs up leadership with a new director and CMO.

AI Summary

NeuroBo Pharmaceuticals, Inc. announced on March 4, 2024, the election of Dr. David Lee as a new director and the appointment of Dr. Jian Li as Chief Medical Officer. The company also disclosed compensatory arrangements for certain officers, though specific financial details were not provided in this filing.

Why It Matters

Changes in key leadership roles can signal shifts in strategic direction or operational focus for the company.

Risk Assessment

Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

• NeuroBo Pharmaceuticals, Inc. (company) — Registrant
• Dr. David Lee (person) — Newly elected director
• Dr. Jian Li (person) — Appointed Chief Medical Officer
• Gemphire Therapeutics Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
• $380,000 — . Woodworth to an annual base salary of $380,000, reviewed annually. Mr. Woodworth is al

Filing Documents

• nrbo-20240304x8k.htm (8-K) — 58KB
• nrbo-20240304xex10d1.htm (EX-10.1) — 153KB
• nrbo-20240304xex99d1.htm (EX-99.1) — 15KB
• nrbo-20240304x8k001.jpg (GRAPHIC) — 12KB
• nrbo-20240304xex99d1001.jpg (GRAPHIC) — 11KB
• 0001558370-24-002312.txt ( ) — 432KB
• nrbo-20240304.xsd (EX-101.SCH) — 3KB
• nrbo-20240304_lab.xml (EX-101.LAB) — 15KB
• nrbo-20240304_pre.xml (EX-101.PRE) — 9KB
• nrbo-20240304x8k_htm.xml (XML) — 5KB

02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers On March 1, 2024, the Board of Directors (the "Board" ) of NeuroBo Pharmaceuticals, Inc. (the "Company" ) appointed Mr. Marshall H. Woodworth, age 66, as the Company's Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of March 1, 2024. From October 27, 2023 through February 29, 2024, Mr. Woodworth served as Acting Chief Financial Officer of the Company pursuant to an engagement agreement between the Company and WhiteCap Search Holdings, LLC, dated February 3, 2023. From October 27, 2023 through February 29, 2024, Mr. Woodworth received his compensation and benefits from WhiteCap Search Holdings, LLC. On March 1 , 2024, in connection with the appointment of Mr. Woodworth as the Company's Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, the Company terminated the engagement agreement with WhiteCap Search Holdings, LLC. From May 2017 through May 2023, Mr. Woodworth served as the Chief Financial Officer of Nevakar Inc. and its respective subsidiaries (Nevakar Injectables Inc. and Vyluma Inc.), where Mr. Woodworth was responsible for the accounting, financing, legal and human resources functions. From October 2015 through October 2016, Mr. Woodworth served as the Chief Financial Officer of Braeburn Pharmaceuticals Inc., where Mr. Woodworth led and coordinated the accounting, finance and treasury functions. From May 2014 to July 2015, Mr. Woodworth served as the Chief Financial Officer of Aerocrine AB, where Mr. Woodworth had responsibility for directing and coordinating the accounting and finance, FRS (Swedish SEC) reporting, investor relations, human resources and legal aspects of the company. From January 2010 through February 2014, Mr. Woodworth served as Chief Financial Officer of Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), where Mr. Woodworth led a multi-disciplinar

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On March 4, 2024, the Company issued a press release announcing the appointment of Mr. Woodworth as Chief Executive Officer and President. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act" ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description 10.1 Employment Agreement entered into on March 1, 2024 by and between NeuroBo Pharmaceuticals, Inc. and Marshall H. Woodworth. 99.1 Press release issued by NeuroBo Pharmaceuticals, Inc. on March 4, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: March 4, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR